Vidac Pharma

What Vidac Pharma does

Vidac Pharma is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapies that selectively modulate the Hexokinase-2 (HK2) and voltage-dependent anion channel (VDAC) protein-protein interaction to disrupt cancer cell metabolism. Founded in Israel by Dr. Max Herzberg in 2012, the company operates as a UK-incorporated public holding company (Vidac Pharma Holding PLC) with its R&D subsidiary (Vidac Pharma Ltd.) based in Rehovot, Israel, in the Weizmann Science Park. Its lead candidate VDA-1102 is a topical ointment in Phase 2b trials for Actinic Keratosis (AK) and in Phase 2a/2 for Cutaneous T-cell Lymphoma (CTCL); the systemic candidates VDA-1102 IV and next-generation VDA-1275 are in preclinical and early-stage development for solid tumors including prostate, pancreatic, lung, cervical, liver, and colorectal cancers. The platform is supported by the proprietary HEXAGON bioinformatics tool, used to identify patients with high HK2-expressing tumors, and is protected by seven global patent families across the US, Canada, China, Japan, and Australia.

Clinical data reported include a Phase 2a interim analysis in CTCL showing a 56% objective response rate (22% complete response) at 8-12 weeks, and a Phase 2b AK study in which patients with good drug penetration (50% of cohort) achieved 40% complete clearance with 80% lesion reduction after 7-8 weeks of treatment. In preclinical studies VDA-1275 reduced required chemotherapy concentrations by 50% (Sorafenib) to 95% (Cisplatin) in liver cancer organoid models. The platform was granted Seal of Excellence by the EU Horizon Europe EIC Accelerator program in 2023, and the company has extended the platform into psoriasis through a PharmaLegacy preclinical program and signed a research cooperation with Sheba Medical Center to investigate synergies with CAR-T cell immunotherapy via tumor microenvironment modification.

Vidac is pre-revenue and intends to monetize drug candidates through licensing agreements, co-development partnerships, or direct commercialization upon regulatory approval. Cumulative capital raised includes approximately USD 22.8 million from private investors since 2012, USD 4.9 million from Israeli CSO and innovation authorities, a EUR 20 million GEM Global Yield committed equity facility that expired undrawn in April 2023, and a small December 2025 public offering of EUR 18,900 on the Düsseldorf Stock Exchange. The company is publicly listed on Hamburg, Stuttgart, Düsseldorf, Xetra, and Tradegate under ticker T9G and is in advanced negotiations to join the Quest for Health accelerator in Strasbourg, France, to anchor continental European expansion.

Name

Vidac Pharma

Legal name

Vidac Pharma Holding PLC

Website

https://vidacpharma.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Vidac Pharma is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapies that selectively disrupt HK2-VDAC protein interactions to induce apoptosis in cancer cells while sparing normal tissue; lead candidate VDA-1102 is in Phase 2b for Actinic Keratosis and CTCL.

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Cancer metabolism therapeutics
• Clinical stage biopharmaceuticals
• Onco-dermatology treatments
• Small molecule drug development
• HK2 VDAC modulators

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, Vidac Pharma does not yet generate product revenue. The company is advancing VDA-1102 through Phase 2b clinical trials for Actinic Keratosis and CTCL, with the long-term intent to commercialize its drug candidates upon regulatory approval.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Vidac Pharma is a clinical-stage biopharmaceutical company developing first-in-class small molecule drug candidates that selectively disrupt the binding of Hexokinase-2 (HK2) to the voltage-dependent anion channel (VDAC) on mitochondria, inducing apoptosis in cancer cells while sparing normal tissue. The lead candidate VDA-1102 is being advanced as a topical ointment for Actinic Keratosis (Phase 2b) and Cutaneous T-cell Lymphoma (Phase 2a), with VDA-1102 IV and VDA-1275 as systemic candidates for solid tumors, supported by the proprietary HEXAGON bioinformatics tool for patient selection.

Product overview

Vidac Pharma is a clinical-stage biopharmaceutical company developing first-in-class cancer therapies based on a novel approach to cancer metabolism targeting the Warburg effect and VDAC/HK2 protein interactions. The company's pipeline consists of three drug candidates: VDA-1102 (topical ointment) as the lead candidate in Phase 2B for Actinic Keratosis and CTCL; VDA-1102 IV for systemic solid tumor treatment; and VDA-1275 as a next-generation systemic candidate for solid tumors. These small molecule drugs function as allosteric protein-protein interaction disruptors that modulate the HK2 metabolic checkpoint to restore normal cellular metabolism and selectively induce programmed cell death in cancer cells.

Differentiator

Problem solved

Functional benefit

Products and services

• VDA-1102 Topical Ointment Proprietary small molecule topical ointment that selectively modulates the VDAC/HK2 interaction to induce apoptosis in cancer cells with minimal effects on surrounding normal tissue. Being developed for high-risk Actinic Keratosis (Phase 2b, 39 patients enrolled at Centroderm GmbH) and Cutaneous T-cell Lymphoma (Phase 2a, 56% objective response rate observed).
• VDA-1102 IV Intravenous formulation of VDA-1102 being developed as a systemic antineoplastic treatment for solid tumors. Selectively modulates VDAC/HK2 to target glycolysis and mitochondrial function in cancer cells and activated immune cells.
• VDA-1275 Next-generation systemic small molecule New Chemical Entity (NCE) with novel mechanism of action that selectively modulates the VDAC/HK2 interaction. Highly potent across a broad spectrum of solid tumors in vitro, with up to 100x greater potency than VDA-1102 in preclinical studies and demonstrated synergy reducing required chemotherapy doses by 50-95% in liver cancer organoid models.

Quantifiable outcome

• Phase 2b study: 40% complete clearance and 80% lesion reduction in patients with good drug penetration (50% of patients) after 7-8 weeks treatment with VDA-1102 ointment in Actinic Keratosis
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Quest for HealthcoreStrategic or Co-development PartnerVidac Pharma is in advanced negotiations to potentially join Quest for Health, a leading European life sciences and healthcare innovation accelerator headquartered in Strasbourg, France. Quest for Health brings together biotech companies, pharmaceutical developers, academic institutions, hospitals, investors, and research organizations. More than EUR 220 million has been raised by 65 startups within the ecosystem over the last three years, with 7 startups being EIC Accelerator laureates. Vidac Pharma is evaluating the establishment of operational and business development activities in the Strasbourg region as part of its strategic expansion into continental Europe. A final decision is expected by end of July 2026.
• Sheba Medical Center (Tel Hashomer)minorStrategic or Co-development PartnerResearch cooperation and licensing agreement with Sheba Medical Center for modification of tumor microenvironment (TME) triggered by Vidac's new chemical drug candidates, to facilitate CAR-T cell immunotherapy. Dr. Elad Jacoby's group at Sheba's Safra Children's Hospital is collaborating with Vidac's R&D team to investigate synergies. The collaboration addresses the lactate-producing hyperglycolysis in the TME, which creates unfavorable conditions for CAR-T treatment.
• Centroderm GmbHcoreImplementation/ SI/ Consulting PartnerPartnership with Centroderm GmbH (Wuppertal, Germany) for conducting the Phase 2b clinical study of VDA-1102 for advanced Actinic Keratosis. Led by Prof. Thomas Dirschka, a world-renowned key opinion leader in dermatology. Centroderm provides full clinical research capacity including patient selection, treatment, and monitoring for high-risk AK patients at the dermatology clinic.
• PharmaLegacyminorImplementation/ SI/ Consulting PartnerContract research organization (CRO) engaged by Vidac Pharma to conduct the in vivo preclinical program evaluating its HK2/VDAC targeting approach for psoriasis. PharmaLegacy brings expertise in dermatology and inflammatory disease models to generate foundational data on whether targeting HK2-VDAC signaling can normalize keratinocyte proliferation and the inflammatory microenvironment in psoriasis.
• ForschungsdockminorImplementation/ SI/ Consulting PartnerContract research organization (CRO) engaged alongside Centroderm GmbH for the Phase 2b clinical study in advanced Actinic Keratosis. Forschungsdock supports protocol development and clinical trial management.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/VidacPharma
• LinkedInlinkedin.com/company/3121139

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vidac Pharma